B. Riley Securities Maintains Buy on Novavax, Raises Price Target to $29
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities has maintained its Buy rating on Novavax (NASDAQ:NVAX) and raised the price target from $11 to $29.
May 23, 2024 | 1:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
B. Riley Securities has maintained its Buy rating on Novavax and significantly raised the price target from $11 to $29, indicating strong confidence in the company's future performance.
The significant increase in the price target from $11 to $29 by B. Riley Securities suggests a strong positive outlook for Novavax. This is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100